^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Excerpt:
...exon19 deletion, L858R mutation, and/or T790M....
Trial ID:
Source:
Title:
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is...
Trial ID:
More C2 evidence
Source:
Title:
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and that is permitted in the osimertinib national label (such as exon 19 deletion and/or L858R), which is...
Trial ID:
Source:
Title:
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico
Excerpt:
...- Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. ...
Trial ID:
Source:
Title:
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib
Excerpt:
...All genders are permitted.- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.- Documented radiologic disease progression on first line osimertinib.- MET-amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.- Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional tissue for central testing which fulfils the following requirements: Obtained following progression on previous osimertinib therapy; obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. ...
Trial ID:
Less C2 evidence
Source:
Title:
Abstract 3017: Using a pharmacodynamic biomarker led approach to explore and quantify the combination effect of savolitinib and osimertinib in the LG1208 NSCLC PDX model
Published date:
05/15/2020
Excerpt:
Combination efficacy of savolitinib and osimertinib was tested in an EGFRm (L858R) and MET-amplified LG1208 PDX model, resistant to osimertinib...Upon combination, at a fixed dose of osimertinib (10 mg/kg), anti-tumor activity increased with savolitinib dose, ranging from 1 mg/kg (99.8 % TGI) to 15 mg/kg (77.9% regression).
DOI:
10.1158/1538-7445.AM2020-3017
